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The B-cell transmembrane protein CD72 binds to and is an in
vivo substrate of the protein tyrosine phosphatase SHP-1
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Pawson*°, Joan Wither†¶#, Benjamin G. Neel§ and Nobumichi Hozumi*†¥
Background: Signals from the B-cell antigen receptor (BCR) help to
determine B-cell fate, directing either proliferation, differentiation, or growth
arrest/apoptosis. The protein tyrosine phosphatase SHP-1 is known to
regulate the strength of BCR signaling. Although the B-cell co-receptor
CD22 binds SHP-1, B cells in CD22-deficient mice are much less severely
affected than those in SHP-1-deficient mice, suggesting that SHP-1 may
also regulate B-cell signaling by affecting other signaling molecules.
Moreover, direct substrates of SHP-1 have not been identified in any B-cell
signaling pathway.
Results: We identified the B-cell transmembrane protein CD72 as a new
SHP-1-binding protein and as an in vivo substrate of SHP-1 in B cells. We also
defined the binding sites for SHP-1 and the adaptor protein Grb2 on CD72.
Tyrosine phosphorylation of CD72 correlated strongly with BCR-induced
growth arrest/apoptosis in B-cell lines and in primary B cells. Preligation of
CD72 attenuated BCR-induced growth arrest/death signals in immature and
mature B cells or B-cell lines, whereas preligation of CD22 enhanced BCR-
induced growth arrest/apoptosis.
Conclusions: We have identified CD72 as the first clear in vivo substrate of
SHP-1 in B cells. Our results suggest that tyrosine-phosphorylated CD72 may
transmit signals for BCR-induced apoptosis. By dephosphorylating CD72,
SHP-1 may have a positive role in B-cell signaling. These results have
potentially important implications for the involvement of CD72 and SHP-1 in 
B-cell development and autoimmunity.
Background
The intensity of signals from the B-cell antigen receptor
(BCR) is a key determinant of the outcome of antigenic
stimulation. BCR engagement activates several protein
tyrosine kinases, leading to the tyrosine phosphorylation
of many downstream signaling molecules [1]. Other B-cell
surface molecules (for example co-receptors) modulate the
BCR signal so that appropriate responses are generated
[2,3]. A critical intensity of BCR signaling is required for
survival and proliferation (positive selection); more
intense signals evoke anergy or deletion (negative selec-
tion) [2,3]. As B cells mature, the threshold for deletion is
increased, with more intense BCR stimulation required
for growth arrest/cell death [4]. The precise mechanism by
which early signaling events are integrated and translated
into B-lymphocyte responses remains unclear.
The protein tyrosine phosphatase (PTP) SHP-1 is a nega-
tive regulator of many hematopoietic signaling pathways,
as illustrated by the phenotype of mice lacking SHP-1
expression — motheaten (me/me) — or expressing defective
SHP-1 — motheaten viable (mev/mev) [5]. SHP-1 binds to
and is activated by members of a family of inhibitory
receptors, which deliver SHP-1 to the vicinity of activating
receptors and/or their substrates [5,6]. These inhibitory
receptors contain at least one copy of the consensus amino-
acid sequence I/V/LXpYXXL/V (in single-letter amino-
acid code), termed the immunoreceptor tyrosine-based
inhibitory motif (ITIM), in their intracellular domains.
Upon tyrosine phosphorylation, ITIMs are specifically rec-
ognized by the SH2 domains of SHP-1, its relative SHP-2
and/or the inositol monophosphatase SHIP [5–9].
BCR responsiveness is markedly enhanced in SHP-1-defi-
cient B cells, indicating that SHP-1 negatively regulates
BCR signaling [10,11]. SHP-1 appears to act, at least in
part, by binding to the inhibitory co-receptor CD22
[12–14]. SHP-1 binds phosphotyrosine peptides based on
Addresses: *Program in Molecular Biology and
Cancer, Samuel Lunenfeld Research Institute, Mount
Sinai Hospital and †Department of Immunology,
University of Toronto, Toronto, Ontario, Canada
M5G 1X5. §Cancer Biology Program, Division of
Hematology-Oncology, Department of Medicine,
Beth Israel Deaconess Medical Center, Boston,
Massachusetts 02215, USA. ¶Toronto Hospital
Research Institute, Toronto, Ontario, Canada M5T
2S8. ¥Research Institute of Biological Sciences,
Science University of Tokyo, Noda-Shi, Chiba, Japan
278. IIDepartment of Pathology, Tokai University
School of Medicine, Isehara, Kanagawa, Japan 259-
11. °Department of Molecular and Medical Genetics
and #Department of Medicine University of Toronto,
Toronto, Ontario, Canada M5G 1X5.
Correspondence: Benjamin G. Neel and Nobumichi
Hozumi 
E-mail: bneel@bidmc.harvard.edu and
nobhozmi@rs.noda.sut.ac.jp
‡Y.W. and M.J.S.N. contributed equally to this work
Received: 1 July 1998
Revised: 6 August 1998
Accepted: 12 August 1998
Published: 26 August 1998
Current Biology 1998, 8:1009–1017
http://biomednet.com/elecref/0960982200801009
© Current Biology Ltd ISSN 0960-9822 
Research Paper 1009
the CD22 ITIMs, and preligation of CD22 on B cells
(which presumably sequesters CD22 from the BCR
complex) markedly lowers the threshold for BCR stimula-
tion [12]. Primary B cells from CD22–/– mice and CD22-
deficient B-cell lines exhibit enhanced calcium flux upon
BCR stimulation, consistent with a negative regulatory
role for the CD22–SHP-1 complex [15–19]. However, the
B-cell phenotype in CD22–/– mice and cell lines is much
less severe than that produced by SHP-1 deficiency
[15–19]. Thus, SHP-1 may also act via other molecules.
Recent studies suggest that the transmembrane glycopro-
tein PIR-B/p91A may be one such molecule [20,21], but
additional regulators of SHP-1 function in B cells have not
been excluded.
Although several molecules that bind to the SH2 domains
of SHP-1 have been defined, no direct targets of SHP-1 in
B cells have been identified. The identification of SHP-1
targets is essential for understanding how SHP-1 regulates
B-cell activation and how the absence of SHP-1 leads to
altered B-cell development and signaling. Here, we have
shown that the transmembrane protein CD72 binds SHP-1
and we have identified CD72 as a direct SHP-1 target.
CD72 tyrosine phosphorylation strongly correlates with
BCR stimuli that lead to B-cell growth arrest/cell death,
and antibody ligation experiments suggest that tyrosine-
phosphorylated CD72 may transmit signals leading to B-
cell death. Moreover, ligation of CD22 and CD72 have
opposite effects on the outcome of BCR activation. Our
results suggest that the tyrosine phosphorylation status of
CD72 may help to determine the outcome of BCR
engagement and suggest a new role for SHP-1 in regulat-
ing signals from CD72.
Results
Identification of the 44 kDa SHP-1-associated tyrosine
phosphoprotein as CD72
A 44 kDa phosphotyrosine protein (pp44) co-immuno-
precipitates with SHP-1 only under conditions in which
B-cell lines or normal B cells respond to BCR stimulation
by undergoing growth arrest/apoptosis [22]. For example,
in Wδ, a derivative of the immature B-cell line WEHI-
231 which expresses endogenous surface immunoglobu-
lin M (sIgM) and exogenous (transfected) surface IgD
(sIgD), crosslinking of sIgM, but not sIgD, leads to
growth arrest and apoptosis [23]. Although nearly all
early signaling events mediated by sIgM and sIgD are
identical in Wδ cells [22–24] (see also below),
pp44–SHP-1 association was observed only upon sIgM
stimulation ([22]; see also Figure 1a). Notably, the
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Figure 1
Identification of SHP-1-associated pp44 as
CD72. (a) SHP-1 or CD72
immunoprecipitates (IPs) from unstimulated
(–) Wδ cells or Wδ cells stimulated for 1 min
with Bet-2 anti-IgM antibody (µ), anti-Sp6 anti-
IgD antibody (δ) or pervanadate (P), as
indicated, were analyzed by anti-
phosphotyrosine (PY) immunoblotting (upper
blots). The positions of known proteins,
including immunoglobulin heavy chains (IgH),
are indicated between the two blots and
numbers on the left are molecular weight
markers in kDa. Blots were sequentially
reprobed for SHP-1 and CD72 (middle and
lower gels). Note that the blotting antibody for
CD72 (directed against the CD72
cytoplasmic domain) recognizes tyrosine-
phosphorylated CD72 poorly. (b) SHP-1 (S)
and CD72 (C) IPs from Bet-2-stimulated Wδ
cells were treated with or without peptide N-
glycanase F (PNGF) before analysis by anti-
PY blotting. The positions of IgH and CD72
before and after treatment are indicated. 
(c) Pervanadate-stimulated Wδ lysates were
immunoprecipitated with SHP-1 antibody
(lane 1) or were allowed to bind to
GST–(C/S)SHP-1 (lane 2) or GST–Grb2
SH2 domain (lane 3) fusion proteins. Bound
proteins were either eluted directly with
SDS–PAGE sample buffer (lanes 1, 2, and 3
respectively), or were eluted with 50 mM free
phosphotyrosine, followed by 
re-immunoprecipitation (re-IP) with anti-CD72
antibodies (lanes 4, 5, and 6 respectively).
Direct eluates and CD72 re-IPs were analyzed
by anti-PY blotting. (d) Pervanadate-stimulated
Wδ lysates were immunoprecipitated with
SHP-1 (lane 1) or CD72 (lane 2) antibodies,
or were allowed to bind to GST–Grb2 SH2
domain (lane 3) or GST–(C/S)SHP-1 (lane 4)
fusion proteins. Bound proteins were resolved
by SDS–PAGE and the corresponding
44 kDa regions were excised from the gel and
then subjected to phosphotyrosine peptide
mapping using V8 protease.
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CD22–SHP-1 complex was induced upon engagement of
either sIgM or sIgD (Figure 1a). Following treatment
with the global PTP inhibitor pervanadate, the
pp44–SHP-1 complex was detected in all B cells ana-
lyzed (Figure 1a and data not shown), suggesting that
tyrosine phosphorylation, not expression, of pp44 is regu-
lated differentially in different B cells.
Biochemical studies indicated that pp44 is a disulfide-
linked surface glycoprotein that binds directly to the SH2
domains of SHP-1 and the adaptor protein Grb2 in a phos-
photyrosine-dependent manner in vivo and in vitro (Figure
1c and data not shown). These properties were reminiscent
of CD72, a disulfide-linked homodimer of a type II trans-
membrane glycoprotein which is expressed selectively in B
cells and contains two ITIMs [25,26] (Figure 2a).
Multiple lines of evidence indicate that pp44 is CD72.
Like pp44, CD72 was tyrosine-phosphorylated in Wδ cells
upon anti-IgM crosslinking or pervanadate treatment, but
not following anti-IgD stimulation (Figure 1a). CD72 and
pp44 co-migrated before and after treatment with N-gly-
canase F (Figure 1b). SHP-1 was detected in CD72
immunoprecipitates prepared from pervanadate-stimu-
lated cells (Figure 1a). A fusion protein comprising glu-
tathione-S-transferase (GST) fused to catalytically
inactive SHP-1 (GST–(C/S)SHP-1) or a fusion protein
comprising GST fused to the SH2 domain of Grb2
(Figure 1c, lanes 1–3) bound to pp44. Treatment of these
complexes with phosphotyrosine (50 mM) led to elution
of pp44, which could be immunoprecipitated with anti-
CD72 antibodies (Figure 1c, lanes 4–6). These data and
phosphatase protection assays (Figure 3) indicate a direct
interaction between the SH2 domain(s) of SHP-1 and one
or more CD72 tyrosine phosphorylation sites. Finally, V8
partial peptide maps of pp44 and CD72 were identical
(Figure 1d). Together, these results identify CD72 as the
SHP-1-associated and Grb2-associated pp44 protein.
Distinct sequences within CD72 mediate SHP-1 and Grb2
binding
CD72 contains two ITIMs (Figure 2a). The second ITIM
is also a potential Grb2-binding sequence (pYXNX) [27].
We identified the binding sites for SHP-1 and Grb2 on
CD72 by phosphotyrosine peptide binding and competi-
tion studies. A phosphopeptide based on the first ITIM of
CD72 (Figure 2a) disrupted the CD72–SHP-1 complex at
50 nM; a phosphopeptide based on the second ITIM
(peptide 2, Figure 2a) failed to compete even at 1 µM
(Figure 2b). Conversely, when coupled to beads, peptide
2 (14 pmol), but not peptide 1 (at greater than 350 pmol),
bound to Grb2 from Wδ lysates (Figure 2c). The respec-
tive dephosphopeptides were inactive in these assays
(Figure 2b,c). Neither peptide 1 nor peptide 2 alone pre-
cipitated SHP-1 from Wδ lysates (data not shown), sug-
gesting that two appropriately oriented ITIMs present in a
CD72 dimer may be required for high-avidity binding to
the tandem SH2 domains of SHP-1, as reported for SHP-1
binding to killer inhibitory receptors (KIRs) on natural
killer (NK) cells [28].
CD72 is a substrate for SHP-1
One reason why SHP-1 might be recruited to CD72 would
be to catalyze CD72 dephosphorylation. To determine
whether CD72 is an SHP-1 target in vivo, we used a set of
B-cell lines derived from me/me mice (ME) and reconsti-
tuted with wild-type SHP-1 or various SHP-1 mutants.
SHP-1 contains three domains capable of binding phos-
photyrosine proteins (its two SH2 domains and its PTP
domain), making it difficult to easily distinguish bona fide
SHP-1 targets from phosphotyrosine proteins that merely
bind SHP-1 through its SH2 domains. To resolve this
Research Paper  SHP-1–CD72 interaction in B cells Wu et al.    1011
Figure 2
CD72 ITIMs mediate binding to SHP-1 and
Grb2. (a) Sequence of the amino-terminal half
of the intracellular domain of CD72.
Sequences of the two biotinylated tyrosine
phosphopeptides (peptides 1 and 2) used in
(b) and (c) are underlined. (b) SHP-1 IPs
prepared from membrane fractions of Wδ
cells stimulated with anti-IgM (Bet-2) antibody
in the presence of the indicated
concentrations of peptide 1 or 2 were
analyzed by anti-PY blotting. In the right panel,
the indicated amounts of peptide 1 were
pretreated with GST (–) or GST–SHP-1 (+)
before addition to the IP mixtures. Numbers
on the left are molecular weight markers in
kDa. (c) Unstimulated Wδ lysates were
incubated with streptavidin–agarose beads
pre-adsorbed with the indicated amounts of
biotinylated peptides. Bound proteins and a
fraction of the total lysates were analyzed by
anti-Grb2 blotting. Where indicated, peptide
2 was pretreated with either GST (–) or
GST–SHP-1 (+) as in (b) before adsorption
to the beads.
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issue, we exploited the distinct properties of different cat-
alytically impaired SHP-1 mutants (Figure 3a). Two of
these — C/S (Cys453Ser) and D/A (Asp419Ala) — should
retain substrate-binding ability (‘trapping’ mutants)
[29–33]. The other mutants — ∆P, which has an internal
PTP domain deletion (residues 451–475), and R/M
(Arg459Met), which replaces an arginine residue that is
essential for binding the phosphate group of substrates
[29–33] — should be unable to bind substrates via their
PTP domains (Figure 3a). Phosphotyrosine proteins that
bind to the C/S or D/A PTP domains (and therefore repre-
sent putative SHP-1 targets) in addition to the SH2
domains present in all of the SHP-1 expression constructs
should exhibit higher-avidity binding than those that bind
to the SH2 domains alone. Also, tyrosine phosphorylation
sites bound by the C/S or D/A PTP domains should be
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Figure 4
CD72 tyrosine phosphorylation correlates with BCR-mediated
inhibition of cell growth. (a) WEHI-231 cells were pretreated with anti-
CD72 ascites or media (control) for 1 h before the addition of varying
amounts of anti-IgM Bet-2 antibody, and [3H]thymidine incorporation
was determined. In these assays, reduced thymidine uptake correlates
with increased apoptosis (Y.W., unpublished observations). Where
error bars are not visible, the standard deviation is smaller than the size
of the symbol. (b) WEHI-231 cells were pretreated with or without
anti-CD72 ascites for 1 min before stimulation with Bet-2 for 1 min.
CD72 IPs and total cell lysates were analyzed by anti-PY blotting and
anti-CD72 reblotting. Total cell lysates were also probed with anti-
phosphoErk and anti-Erk2 antibodies, as indicated. (c) Mature primary
B cells were precultured with or without anti-CD72 ascites as in (a) for
1 h before the addition of varying amounts of biotinylated Bet-2 or
Hδa/1 antibody and, where indicated, a twofold excess (w/w) of avidin,
and [3H]thymidine incorporation was determined. (d) Mature and
immature Balb/c B cells were pretreated with or without anti-CD72
ascites as in (a) for 1 h before the addition of varying amounts of
(Fab′)2 goat anti-mouse IgM antibody. Proliferation was assayed as in
(c). (e) Immature and mature B cells were subjected to BCR
crosslinking by biotinylated Bet-2 (µ) or Hδa/1 (δ) antibody alone or
hyper-crosslinking with additional avidin (Av) at twofold excess (w/w)
for 1 min. Where indicated, cells were pretreated with anti-CD72
ascites as in (b). CD72 IPs were analyzed by anti-PY blotting and anti-
CD72 reblotting. (f) WEHI-231 cells were pretreated with the
indicated reagents (where the control was an isotype-matched non-
specific antibody) and monoclonal antibody 2.4G2 to block FcγRIIB
binding, before the addition of (Fab′)2 goat anti-mouse IgM antibody.
[3H]Thymidine incorporation was determined as in (a). The mean value
of the untreated samples was defined as 100%. The asterisk indicates
p < 0.005 (one-tailed t-test) as compared with the corresponding value
for pretreatment with no antibody. Under the same conditions,
pretreatment with anti-CD72 antibody antagonized growth inhibition as
shown in (a). (g) WEHI-231 cells were pretreated with anti-CD72 or
anti-CD22 antibody for 1 min before (Fab′)2 goat anti-mouse IgM
antibody stimulation for a further minute. CD72 IPs were analyzed by
anti-PY blotting and anti-CD72 reblotting. This panel is representative
of three independent experiments with similar results. (h) CD72
ligation has no effect on BCR-evoked calcium response. Fura-2-loaded
WEHI-231 cells were pretreated with anti-CD72 antibodies or with
control, isotype-matched non-specific antibodies, followed by BCR
stimulation (indicated by anti-µ), and measurement of calcium flux.
Figure 3
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(a)
CD72 is a direct substrate of SHP-1. (a) Schematic representation of
SHP-1 mutants with different amino-acid substitutions and their
predicted effects on a hypothetical ITIM-containing protein. Increased
binding/protection is expected with trapping mutants compared with
non-trapping mutants. (b) SHP-1 IPs from unstimulated or anti-IgM
(Bet-2)-stimulated SHP-1–/– B-cell lines reconstituted with expression
vector alone (ME) or the various indicated mutant forms of SHP-1 were
analyzed by anti-PY blotting and anti-SHP-1 reblotting: WT, wild type.
Bands overlapping the IgH chains in the ∆P lanes were not observed
reproducibly. (c) CD72 IPs from various cell lines were analyzed as in
(b). (d) In vitro PTP protection assays (see Materials and methods and
Results) were performed on the indicated Bet-2-stimulated cell lines.
CD72 IPs were analyzed by anti-PY blotting and anti-CD72 reblotting.
Similar results were obtained when the corresponding SHP-1 IPs were
analyzed (data not shown). (e) SHP-1 IPs from unstimulated and anti-
IgM-stimulated splenic B cells from wild-type or mev/mev mice were
analyzed by anti-PY blotting and anti-SHP-1 reblotting. Numbers on
the left are molecular weight markers in kDa.
protected from dephosphorylation by cellular PTPs. Thus,
in vivo substrates of SHP-1 should exhibit greater tyrosine
phosphorylation in the presence of C/S or D/A mutants
than with comparable amounts of R/M or ∆P mutants.
BCR-evoked CD72 tyrosine phosphorylation
(Figure 3c,d) and association with SHP-1 (Figure 3b,
except in ME cells, which lack SHP-1) were observed in
the vector control and all four mutant (but not wild-type)
SHP-1-expressing lines. All cell lines except wild-type
SHP-1-reconstituted cells exhibited enhanced (Figure 3b)
and prolonged CD72 tyrosine phosphorylation ([22] and
data not shown). Thus, some of the increased CD72 tyro-
sine phosphorylation observed in the presence of catalyti-
cally impaired mutants of SHP-1 is due to ‘protection’ by
the SHP-1 SH2 domains; this finding provides additional
evidence that SHP-1 interacts directly, through its SH2
domains, with tyrosine-phosphorylated CD72. However,
CD72 tyrosine phosphorylation was much higher in the
cell lines reconstituted with the C/S or D/A mutants of
SHP-1 than in those reconstituted with R/M or ∆P
mutants, indicating that additional protection was afforded
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by ‘trapping’ mutants of SHP-1 (Figure 3b,c). These
results suggest that CD72 is an SHP-1 substrate in vivo.
To confirm these findings, we used a novel in vitro PTP
protection assay, which compares the ability of SHP-1
mutants to protect CD72 from dephosphorylation by cel-
lular PTPs. ME cells expressing mutant SHP-1 or vector
controls were stimulated briefly by BCR crosslinking,
then lysed in the absence of PTP inhibitors and incubated
for various times (see Materials and methods). The C/S
and D/A, but not the ∆P or R/M, mutants of SHP-1
offered significant protection from dephosphorylation by
cellular PTPs (Figure 3d), clearly establishing that CD72
is a target of the SHP-1 PTP domain. Consistent with the
notion that CD72 is an in vivo substrate of SHP-1, tyrosine
phosphorylation of CD72 was increased in primary B cells
from mev/mev mice (Figure 3e). These data also clearly
show that the SHP-1–CD72 complex forms in primary B
cells as well as in B-cell lines.
Tyrosine phosphorylation of CD72 correlates strongly with
BCR-evoked growth arrest/cell death
As nearly all proximal signaling events are comparable fol-
lowing sIgM triggering (leading to tyrosine phosphorylation
of CD72) and sIgD triggering (leading to no CD72 tyrosine
phosphorylation) in Wδ cells (Figure 1a; [22–24]), the
CD72–SHP-1 complex does not appear to act like the
CD22–SHP-1, PIR-B–SHP-1 or KIR–SHP-1 complexes
[5,6,20,21], which interfere with early signaling events.
Instead, the correlation of transient tyrosine phosphoryla-
tion of CD72 (and consequent SHP-1 association) with
BCR-evoked growth arrest/cell death [22], the enhanced B
cell deletion in me/me and mev/mev mice [11] in which CD72
is hyperphosphorylated (Figure 3e), and our demonstration
that CD72 is a direct substrate of SHP-1 (Figure 3), sug-
gested to us that tyrosine-phosphorylated CD72 might
transmit growth arrest/cell-death-inducing signal(s) that are
antagonized by SHP-1-catalyzed dephosphorylation. If so,
specific modulation of CD72 might be expected to alter the
outcome of BCR signaling. Indeed, prior ligation of CD72
protected WEHI-231 cells from anti-IgM-induced growth
arrest (Figure 4a). Notably, anti-CD72 antibody treatment
did not alter BCR-proximal signaling events such as overall
tyrosine phosphorylation, mitogen-activated protein (MAP)
kinase activation or the Ca2+ response (Figure 4b,h).
However, under these conditions, tyrosine phosphorylation
of CD72 was specifically diminished (Figure 4b), support-
ing the possibility that tyrosine-phosphorylated CD72
transmits a growth inhibitory signal.
CD72 tyrosine phosphorylation (and SHP-1 association;
data not shown) also correlated with BCR-induced growth
arrest/cell death in primary B cells. Splenic B cells were iso-
lated from normal mice (mature B cells) and from mice that
had been sublethally irradiated and allowed to self-recon-
stitute (and thus contain predominantly immature B cells)
[34,35]. Treatment of mature B cells with unconjugated or
biotinylated anti-IgM or anti-IgD antibodies evoked prolif-
eration (Figure 4d and data not shown); under these condi-
tions, CD72 was not tyrosine phosphorylated (Figure 4e,
lanes 10 and 12). Delivering a stronger BCR signal to these
cells (by crosslinking the biotinylated antibodies with
avidin) inhibited proliferation and induced apoptosis [4]
(Figure 4c and data not shown). Remarkably, tyrosine
phosphorylation of CD72 was observed only under such
‘enhanced’ BCR stimulation conditions (Figure 4e, lanes
11 and 13). In contrast, unconjugated or biotinylated anti-
IgM antibodies alone were sufficient to induce apoptosis
[35] (Figure 4d and data not shown) and CD72 tyrosine
phosphorylation in immature B cells (Figure 4e, lane 2),
further strengthening the correlation between CD72 tyro-
sine phosphorylation and growth arrest/cell death. Preligat-
ing CD72 attenuated the inhibitory effect of BCR
hyper-crosslinking on mature B-cell growth (Figure 4c),
and induced modest proliferation of anti-IgM-treated
immature B cells (Figure 4d). In both cases (as in WEHI-
231 cells), preligation prevented CD72 tyrosine phosphory-
lation (Figure 4e, lanes 6–8,14,15). Preligation also
enhanced mature B-cell proliferation under normal
crosslinking conditions (Figure 4d), suggesting that CD72
may restrain mature B-cell proliferation even when its tyro-
sine phosphorylation is below the limits of detection.
Opposite functions of CD72 and CD22 in regulating BCR
signaling outcome
To test whether CD22 (and by inference, the CD22–SHP-
1 complex) and CD72 (and the CD72–SHP-1 complex)
have distinct functions in B-cell signaling within the same
cellular context, we examined the effect of CD22 ligation
on BCR signaling in WEHI-231 cells. Contrary to the
effects of CD72 preligation (Figure 4a), preligating CD22
enhanced BCR-induced WEHI-231 cell death (Figure 4f).
Remarkably, preligation of CD22 also enhanced the 
tyrosine phosphorylation of CD72 (Figure 4g). These data
are consistent with our proposal that tyrosine-phosphory-
lated CD72 may mediate growth-inhibitory signals from
the BCR, as well as with the previous finding that CD22
ligation enhances BCR signal strength [12]. Furthermore,
these results suggest that CD72 may be a target for the
CD22–SHP-1 complex.
Discussion
Although several SHP-1-binding proteins have been identi-
fied, the physiological targets of SHP-1 in B-cell signaling
have remained undefined. Our work clearly identifies CD72
as both an SHP-1 binding protein (Figures 1,2) and a direct
substrate for SHP-1 in vivo (Figure 3). As tyrosine phospho-
rylation of CD72 strongly correlates with the ability of the
BCR to deliver growth-inhibitory/apoptosis-inducing signals
(Figure 4), our results suggest that SHP-1-catalyzed dephos-
phorylation of CD72 may antagonize these signals. Such a
model has potentially important implications for how BCR
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signals lead to distinct outcomes in different cellular con-
texts, for the role of SHP-1 in this process, and for the sever-
ity of the B-cell phenotype in SHP-1-deficient mice. 
The use of substrate-trapping mutants to identify SHP-1
targets is complicated by the presence of multiple domains
within SHP-1 capable of binding phosphotyrosine-con-
taining sequences. Our results (Figure 3) clearly illustrate
the perils of assuming that increased phosphorylation of an
SHP-1-binding protein in the presence of a catalytically
impaired mutant alone indicates that that protein is a sub-
strate: expression of either non-trapping or trapping
mutants of SHP-1 leads to increased CD72 tyrosine phos-
phorylation, presumably via SH2-domain-mediated pro-
tection of binding sites from dephosphorylation by other
PTPs. However, trapping mutants cause markedly greater
increases in CD72 phosphorylation, because they also bind
targets through their (impaired) PTP domains. By compar-
ing the effects of both types of mutant, substrates for 
SHP-1 can be identified with confidence.
Tyrosine phosphorylation of CD72 strongly correlates
with BCR signals leading to growth arrest/cell death in
cultured B cell lines (for example WEHI-231) and primary
B cells ([22] and Figure 4). More importantly, our anti-
body ligation studies suggest that CD72 tyrosine phospho-
rylation is causally important for BCR-induced growth
arrest/cell death (Figure 4). Preligating CD72, which
results in decreased CD72 tyrosine phosphorylation while
having little effect on BCR-induced total tyrosine phos-
phorylation, MAP kinase activation or calcium response
(Figure 4b,h), leads to enhanced survival of WEHI-231
and primary B cells (Figure 4a,c,d). Thus, decreasing the
tyrosine phosphorylation of CD72 may contribute to 
B-cell survival following BCR activation (Figure 5a).
Although we favor the notion that CD72 ligation
decreases a negative signal that emanates from tyrosine-
phosphorylated CD72, we cannot exclude the possibility
that CD72 ligation enhances an as yet undefined positive
signal generated by unphosphorylated CD72. Likewise,
although we observed no differences (except CD72 tyro-
sine phosphorylation) in early BCR signaling events in
CD72-ligated cells, it remains possible that other, uniden-
tified signals (including other, as yet unidentified phos-
photyrosine proteins) that antagonize growth arrest and
apoptosis are generated. Analysis of CD72–/– cell lines
and/or mice is required to resolve this issue.
CD22 ligation has the opposite effect in WEHI-231 cells,
leading to enhanced BCR-mediated cell growth
arrest/apoptosis. Earlier antibody ligation and genetic
studies established that CD22 negatively regulates BCR
signal strength most probably through SHP-1. By prevent-
ing CD22–SHP-1 complexes from accessing the BCR,
CD22 antibody ligation would be expected to increase the
effective strength of anti-BCR antibody stimulation, thus
leading to enhanced BCR-induced cell death in immature
B cells [2]. Remarkably, CD22 ligation also leads to
increased CD72 tyrosine phosphorylation (Figure 4g). In
addition to further strengthening the correlation between
CD72 tyrosine phosphorylation and BCR-induced growth
inhibition/cell death, these data suggest that CD22 liga-
tion may exert at least part of its effect by increasing
CD72 tyrosine phosphorylation.
The role we propose for SHP-1 in regulating the CD72
pathway (Figure 5b) contrasts sharply with how SHP-1 is
believed to function upon its association with other ITIM-
bearing molecules, such as CD22, PIR-B and KIRs
[5,6,20,21]. SHP-1 bound to these molecules antagonizes
positive signaling from the BCR (in the case of CD22 and
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Figure 5
(a) Model depicting the role of CD72 and SHP-1 in B cells. CD72 is
shown as a disulfide-linked dimer with a conserved C-type lectin
domain and ITIMs (blue). Tyrosine phosphorylation is indicated by P.
Parameters that influence the balance between protein tyrosine
kinases (PTKs) and SHP-1, which both affect CD72 tyrosine
phosphorylation and B-cell fate, are shown in the box. Lack of SHP-1
activity (as in me/me or mev/mev mice) would result in excessive
negative selection, whereas defects in protein tyrosine kinase(s) acting
on CD72 could lead to altered positive and/or negative selection. 
(b) Distinction between function of SHP-1 bound to tyrosine-
phosphorylated CD22 and CD72, respectively. CD22 has three ITIMs
and three other tyrosine phosphorylation sites (purple) [12]. SHP-1 is
recruited to the ITIMs through its two SH2 domains (orange) before
acting on the substrates through its PTP domain (red). Positive
signaling molecules targeted by CD22-associated SHP-1 remain to be
identified (dashed arrows). Possibilities include BCR-associated
protein tyrosine kinases, CD22 itself, and other tyrosine-
phosphorylated adaptor or effector molecules (X-P).
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PIR-B) or activating NK cell receptors (in the case of
KIRs) by dephosphorylating one or more as yet unidenti-
fied targets. While our manuscript was in preparation,
Adachi et al. [36] also reported that CD72 binds to SHP-1
and, solely on the basis of this interaction, proposed that
CD72 has a negative regulatory role. In contrast, our func-
tional studies (Figure 4) support an alternative model, in
which SHP-1 ‘positively’ promotes B-cell survival and
expansion by inactivating ‘negative’ signals from tyrosine-
phosphorylated CD72 (Figure 5).
The combined loss of CD72–SHP-1 and CD22–SHP-1
complexes in early B cells may help to explain the marked
depletion of B-cell precursors in me/me and mev/mev mice.
Loss of CD22 leads to enhanced signaling through the
BCR and increased tyrosine phosphorylation of CD72
(Figure 4g). Concomitantly, in the absence of SHP-1,
CD72 exhibits enhanced tyrosine phosphorylation, as
CD72 is a direct substrate of SHP-1 (Figure 3). This syner-
gistic effect may also help explain why CD22–/– B cells
(lacking only the CD22–SHP-1 complex) exhibit a much
less severe phenotype than those lacking functional SHP-1
(which lack all functional SHP-1 complexes). Alterna-
tively, as CD22 expression is highest in more mature B
cells, the profound depletion of B-cell precursors that
occurs in SHP-1-deficient mice may be largely due to loss
of the CD72–SHP-1 complex, whereas loss of the
CD22–SHP-1 complex may be more important for other
aspects of the SHP-1-deficient phenotype, such as the
increased activation of more mature B cells. Studies of
mice with compound deficiencies in CD22 and CD72
should provide important insights into these issues.
Materials and methods
Cell and cell lines
Balb/c splenic B cells were purified as described [37], except that
Ficoll was substituted for Percoll. Immature B cells were obtained from
self-reconstituting Balb/c mice as described previously [34,35]. Cell
lines were cultured as described [23]. ME cells [38] were transfected
with vector alone (ME), wild-type SHP-1 cDNA (wt) or various mutant
(Cys453Ser (C/S), Asp419Ala (D/A), residue 415–475-deletion (∆P)
and Arg459Met (R/M)) human SHP-1 cDNAs; these mutants have
been described [33]. Selected clones were matched for sIgM expres-
sion and comparable levels of SHP-1 protein. 
Cell stimulations
Crosslinking of sIgM was carried out using Bet-2 (ATCC) or (Fab′)2
goat anti-mouse µ (Jackson Immunoresearch) antibodies. Anti-Sp6
[23] and Hδa/1 (provided by F. Finkelman, University of Cincinnati) anti-
bodies were for sIgD activation. BCR hyper-crosslinking was achieved
by using biotinylated Bet-2 or Hδa/1 antibodies, respectively, followed
by addition of a twofold excess (w/w) of avidin. Biotinylated antibodies
alone were used for normal crosslinking. Pervanadate was a mixture of
3 mM H2O2 and 1 mM sodium orthovanadate. For CD72 preligation,
ascites or purified anti-CD72 monoclonal antibody K10.6 [39] was
used (CD72.4, Cedarlane Laboratories). Anti-CD22 monoclonal anti-
body NIM-R6 [15] was used for CD22 ligation.
Immunoprecipitation and immunoblotting
Polyclonal antibodies against SHP-1 were from K. Siminovitch (Samuel
Lunenfeld Research Institute, Toronto) or Santa Cruz Biotechnology
(Santa Cruz). CD72 immunoprecipitations were performed with K10.6.
Antibodies for immunoblotting CD72, Grb2, the kinase Erk2 and phos-
phoErk were from Santa Cruz Biotechnology. Anti-phosphotyrosine
monoclonal antibody (4G10) was from UBI. Peptide N-glycanase F
treatment was performed according to the manufacturer (New England
Biolabs). Cell lysis, immunoprecipitation and immunoblotting were per-
formed as described previously [22].
Partial proteolytic mapping with V8 protease
Partial proteolytic mapping with V8 protease (Sigma Chemical) was
carried out on excised gel pieces containing the 44 kDa region as
described [40].
In vitro binding assays
GST fusion protein expression constructs were constructed and purified
on glutathione–Sepharose (Pharmacia Biotech), as described previously
[41,42]. Biotinylated tyrosine-phosphorylated peptides were synthesized
as described [43]. Dephosphopeptides were obtained by treating phos-
phopeptides with GST–SHP-1 bound to glutathione–Sepharose beads
in 62.5 mM Tris pH 7.4/6.25 mM EDTA/10 mM DTT for 1.5 h at 37°C.
Biotinylated peptides were bound to streptavidin–agarose beads (Life
Technologies) and incubated with cell lysates. Bound proteins were
eluted in SDS–PAGE sample buffer or, for re-immunoprecipitation
experiments, in lysis buffer containing 50 mM phosphotyrosine.
In vitro PTP protection assay
Cells were stimulated for 1 min and lysed in NP-40 buffer [22] lacking
PTP inhibitors. Lysates were incubated on ice for various times before
the addition of 1 mM sodium orthovanadate and processing for
immunoprecipitations. For the 0 time point, cells were lysed directly in
orthovanadate-containing buffer.
Proliferation and calcium assays
Proliferation was assayed essentially as described [23]. Specifically,
cells were cultured in triplicate at 2 × 105/ml for WEHI-231 cells (total
of 48 h) and at 7.5 × 105/ml for splenic B cells (total of 42 h) in a total
volume of 200 µl. Where indicated, monoclonal antibody 2.4G2
(Pharmingen) was included to block FcγRIIB binding. [3H]Thymidine
(NEN), 1 µCi per well, was added to the WEHI cultures for the last 6 h
and to the splenic B-cell cultures for the last 18 h. Measurements of
BCR-evoked calcium flux in Fura-2-loaded WEHI-231 cells were
carried out as described previously [15].
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